The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Osteoporosis is a disease where decreased bone strength increases the risk of a broken bone. It is the most common reason for a broken bone among the elderly. Bones that commonly break include the back bones, the bones of the forearm, and the hip. Until a broken bone occurs there are typically no symptoms. Bones may weaken to such a degree that a break may occur with minor stress or spontaneously. Chronic pain and a decreased ability to carry out normal activities may occur following a broken bone.
Osteoporosis may be due to lower than normal peak bone mass and greater than normal bone loss. Bone loss increases after menopause due to lower levels of estrogen. Osteoporosis may also occur due to a number of diseases or treatments including alcoholism, anorexia, hyperthyroidism, surgical removal of the ovaries, and kidney disease. Certain medications increase the rate of bone loss including some antiseizure medications, chemotherapy, proton pump inhibitors, selective serotonin reuptake inhibitors, and steroids. Not enough exercise and smoking are also risk factors. Osteoporosis is defined as a bone density of 2.5 standard deviations below that of a young adult. This is typically measured by dual-energy X-ray absorptiometry at the hip.
The global Osteoporosis Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
In Brazil, Osteoporosis Drugs key players include Eli Lilly, Novartis, Pfizer, etc. Global top three manufacturers hold a share over 35%.
In terms of product, Antiresorptive Drugs is the largest segment, with a share over 70%. And in terms of application, the largest application is Female, followed by Male.
This report aims to provide a comprehensive presentation of the global market for Osteoporosis Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Osteoporosis Drugs.
Report Scope
The Osteoporosis Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Osteoporosis Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Osteoporosis Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
- Eli Lilly
- Novartis
- Pfizer
- Amgen
- Merck
- Novo nordisk
- Actavis
- Roche
Segment by Type
- Antiresorptive Drugs
- Anabolic Drugs
Segment by Application
- Female
- Male
Consumption by Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Russia)
- Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
- Latin America (Mexico, Brazil, Argentina)
- Middle East & Africa (Turkey, Saudi Arabia, UAE)
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Osteoporosis Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Osteoporosis Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index
1 Osteoporosis Drugs Market Overview
1.1 Product Overview and Scope of Osteoporosis Drugs
1.2 Osteoporosis Drugs Segment by Type
1.2.1 Global Osteoporosis Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Antiresorptive Drugs
1.2.3 Anabolic Drugs
1.3 Osteoporosis Drugs Segment by Application
1.3.1 Global Osteoporosis Drugs Market Value by Application: (2024-2030)
1.3.2 Female
1.3.3 Male
1.4 Global Osteoporosis Drugs Market Size Estimates and Forecasts
1.4.1 Global Osteoporosis Drugs Revenue 2019-2030
1.4.2 Global Osteoporosis Drugs Sales 2019-2030
1.4.3 Global Osteoporosis Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Osteoporosis Drugs Market Competition by Manufacturers
2.1 Global Osteoporosis Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Osteoporosis Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Osteoporosis Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Osteoporosis Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Osteoporosis Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Osteoporosis Drugs, Product Type & Application
2.7 Osteoporosis Drugs Market Competitive Situation and Trends
2.7.1 Osteoporosis Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Osteoporosis Drugs Players Market Share by Revenue
2.7.3 Global Osteoporosis Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Osteoporosis Drugs Retrospective Market Scenario by Region
3.1 Global Osteoporosis Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Osteoporosis Drugs Global Osteoporosis Drugs Sales by Region: 2019-2030
3.2.1 Global Osteoporosis Drugs Sales by Region: 2019-2024
3.2.2 Global Osteoporosis Drugs Sales by Region: 2025-2030
3.3 Global Osteoporosis Drugs Global Osteoporosis Drugs Revenue by Region: 2019-2030
3.3.1 Global Osteoporosis Drugs Revenue by Region: 2019-2024
3.3.2 Global Osteoporosis Drugs Revenue by Region: 2025-2030
3.4 North America Osteoporosis Drugs Market Facts & Figures by Country
3.4.1 North America Osteoporosis Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Osteoporosis Drugs Sales by Country (2019-2030)
3.4.3 North America Osteoporosis Drugs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Osteoporosis Drugs Market Facts & Figures by Country
3.5.1 Europe Osteoporosis Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Osteoporosis Drugs Sales by Country (2019-2030)
3.5.3 Europe Osteoporosis Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Osteoporosis Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Osteoporosis Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Osteoporosis Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Osteoporosis Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Osteoporosis Drugs Market Facts & Figures by Country
3.7.1 Latin America Osteoporosis Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Osteoporosis Drugs Sales by Country (2019-2030)
3.7.3 Latin America Osteoporosis Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Osteoporosis Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Osteoporosis Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Osteoporosis Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Osteoporosis Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Osteoporosis Drugs Sales by Type (2019-2030)
4.1.1 Global Osteoporosis Drugs Sales by Type (2019-2024)
4.1.2 Global Osteoporosis Drugs Sales by Type (2025-2030)
4.1.3 Global Osteoporosis Drugs Sales Market Share by Type (2019-2030)
4.2 Global Osteoporosis Drugs Revenue by Type (2019-2030)
4.2.1 Global Osteoporosis Drugs Revenue by Type (2019-2024)
4.2.2 Global Osteoporosis Drugs Revenue by Type (2025-2030)
4.2.3 Global Osteoporosis Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Osteoporosis Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Osteoporosis Drugs Sales by Application (2019-2030)
5.1.1 Global Osteoporosis Drugs Sales by Application (2019-2024)
5.1.2 Global Osteoporosis Drugs Sales by Application (2025-2030)
5.1.3 Global Osteoporosis Drugs Sales Market Share by Application (2019-2030)
5.2 Global Osteoporosis Drugs Revenue by Application (2019-2030)
5.2.1 Global Osteoporosis Drugs Revenue by Application (2019-2024)
5.2.2 Global Osteoporosis Drugs Revenue by Application (2025-2030)
5.2.3 Global Osteoporosis Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Osteoporosis Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Eli Lilly
6.1.1 Eli Lilly Corporation Information
6.1.2 Eli Lilly Description and Business Overview
6.1.3 Eli Lilly Osteoporosis Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Eli Lilly Osteoporosis Drugs Product Portfolio
6.1.5 Eli Lilly Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Corporation Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Osteoporosis Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Novartis Osteoporosis Drugs Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Corporation Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Osteoporosis Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Pfizer Osteoporosis Drugs Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Amgen
6.4.1 Amgen Corporation Information
6.4.2 Amgen Description and Business Overview
6.4.3 Amgen Osteoporosis Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Amgen Osteoporosis Drugs Product Portfolio
6.4.5 Amgen Recent Developments/Updates
6.5 Merck
6.5.1 Merck Corporation Information
6.5.2 Merck Description and Business Overview
6.5.3 Merck Osteoporosis Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Merck Osteoporosis Drugs Product Portfolio
6.5.5 Merck Recent Developments/Updates
6.6 Novo nordisk
6.6.1 Novo nordisk Corporation Information
6.6.2 Novo nordisk Description and Business Overview
6.6.3 Novo nordisk Osteoporosis Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Novo nordisk Osteoporosis Drugs Product Portfolio
6.6.5 Novo nordisk Recent Developments/Updates
6.7 Actavis
6.6.1 Actavis Corporation Information
6.6.2 Actavis Description and Business Overview
6.6.3 Actavis Osteoporosis Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Actavis Osteoporosis Drugs Product Portfolio
6.7.5 Actavis Recent Developments/Updates
6.8 Roche
6.8.1 Roche Corporation Information
6.8.2 Roche Description and Business Overview
6.8.3 Roche Osteoporosis Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Roche Osteoporosis Drugs Product Portfolio
6.8.5 Roche Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Osteoporosis Drugs Industry Chain Analysis
7.2 Osteoporosis Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Osteoporosis Drugs Production Mode & Process
7.4 Osteoporosis Drugs Sales and Marketing
7.4.1 Osteoporosis Drugs Sales Channels
7.4.2 Osteoporosis Drugs Distributors
7.5 Osteoporosis Drugs Customers
8 Osteoporosis Drugs Market Dynamics
8.1 Osteoporosis Drugs Industry Trends
8.2 Osteoporosis Drugs Market Drivers
8.3 Osteoporosis Drugs Market Challenges
8.4 Osteoporosis Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
